AbbVie registers Phase 1 PK study of trosunilimab given IV and SC in healthy adultsNov 13Weekly roundup, 8 itemsABBV-295ABBV-722
Pfizer adds second Phase 3 berobenatide knee osteoarthritis trial, completes Phase 2b VESPER-3Nov 6Weekly roundup, 13 itemsberobenatidemarstacimab-hncqUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
AbbVie posts KEEPsAKE 2 update; registers pediatric vitiligo and real-world MIRV studiesOct 29Weekly roundup, 7 itemsABBV-706ABBV-722Updated
FDA approves efficacy supplement for AbbVie's SkyriziOct 23Regulatory decisionAbbVierisankizumab-rzaa
AbbVie posts results for Japan CLL/SLL study; also files new Phase 3 NSCLC trial vs pembrolizumabOct 23Weekly roundup, 6 itemsABBV-1480AbbVieUpdated
AbbVie's CANASA label update and ABBV-253 trial recruitment lead busy week of registry changesOct 16Weekly roundup, 9 itemsABBV-1042ABBV-253Updated
Spyre Therapeutics files preliminary prospectus for common stock offeringOct 5FinancingSpyre Therapeutics, Inc.
AbbVie to acquire Apogee Therapeutics, updates 2026 EPS guidance amid Q2 resultsJul 31Quarterly updateAbbVie